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Gastric cancer metastasised to the liver was found to overexpress HER2 at a significantly higher incidence than primary gastric
cancers. The purpose of the present study was to investigate the possibility of molecular therapy targeting HER2 overexpression in
gastric cancer liver metastasis. We developed three new HER2-overexpressing gastric cancer cell lines (GLM-1, GLM-2, GLM-4)
without epidermal growth factor receptor (EGFR) mutations derived from such liver metastasis, two of which had HER2 gene
amplifications. All these GLM series of cell lines were highly sensitive to gefitinib in vitro, a specific inhibitor of EGFR tyrosine kinase
(Iressa) rather than anti-HER2 antibody trastuzumab (Herceptin), whereas most of the HER2 low-expressing counterparts were not.
In these HER2-overexpressing GLM series, protein kinase B (Akt), but not extracellular signal-regulated kinase 1/2 (ERK1/2), was
constitutively phosphorylated, and gefitinib efficiently inhibited this Akt phosphorylation, induced strong apoptosis in vitro and
exhibited antitumour activity in tumour xenografts in nude mice. This gefitinib-mediated antitumour effect in xenograft was
significantly potentiated by trastuzumab treatment. On the other hand, gefitinib-resistant cells (GLM-1R) exhibited increased EGFR
expression, followed by constitutive activation of mitogen-activated protein kinase (MAPK) pathway. These results suggest that the
antitumour effect of gefitinib is due to the effective inhibition of HER2-driven constitutive activation of phosphatidylinositol-3-kinase
(PI3K)/Akt pathway, and that the acquired resistance to gefitinib is due to the constitutive activation of Ras/MAPK pathway in
compensation for PI3K/Akt pathway. Gastric cancer liver metastasis with HER2 overexpression would be a potential molecular target
for gefitinib and trastuzumab.
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Although the survival of patients with gastric cancer has improved,
gastric cancer still remains one of the major causes of cancer death
in Japan as well as in some Western countries. Liver metastasis is
an important prognostic factor, accounting for 10–15% of gastric
cancer recurrences after curative resection (Marrelli et al, 2004).
This is a noncurable, fatal disease with a 5-year survival of less
than 10% (Sakamoto et al, 2003). To date, however, the molecular
basis of its growth and metastasis remains essentially unknown,
and there are no effective therapeutic modalities including
molecular targeting therapy.
HER family is a type I receptor tyrosine kinase including HER1
(epidermal growth factor receptor (EGFR)), HER2 (neu/erbB2),
HER3 (erbB3) and HER4 (erbB4) that regulates essential cellular
functions, such as growth, differentiation and apoptosis in normal
tissues, and their activation is associated with carcinogenesis and
progression in solid tumours (Yarden, 2001). The binding of
ligands to the extracellular region of HER family induces receptor
homo- or heterodimerisation and activation of cytoplasmic
tyrosine kinase (TK), which in turn leads to autophosphorylation
and initiation of downstream signalling pathways (Muthuswamy
et al, 1999). Among the members of HER family, HER2 is
overexpressed in 10–30% of patients with gastric cancer and is
known to lead to a poor patient outcome owing to malignant
progression, for example, metastasis and resistance to chemother-
apy such as that found in breast cancer (David et al, 1992; Uchino
et al, 1993). A unique feature of HER2, as revealed by recent
crystallo-structural analysis of HER2 protein, is that HER2 has a
fixed conformation that resembles a ligand-activated state and can
interact with other HER receptors to form EGFR/HER2 and HER2/
HER3 (HER4) heterodimers even in the absence of a cognate
ligand, unlike EGFR and HER3 (HER4) (Cho et al, 2003).
Therefore, HER2 is capable of constitutively transducing signals
downstream to such as the Ras/mitogen-activated protein kinase
(MAPK) and phosphatidylinositol-3-kinase (PI3K)/protein kinase
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sB (Akt) pathways by upregulation of HER2 in addition to the
activation by mutation or amplification in the absence of ligand
binding. Consequently, HER2 overexpression mediates multiple
pathological responses including a chemokine receptor, CXCR4-
associated metastasis (Li et al, 2004) and a multidrug resistance
owing to activation of PI3K/Akt pathway (Knuefermann et al,
2003). These findings suggest that HER2-overexpressing gastric
cancers are potential targets for antitumour molecular therapy.
Gefitinib, an orally active, quinazoline tyrosine kinase inhibitor
selective for EGFR, has been proved to have a clinically significant
antitumour activity in lung cancers, and is now approved for use
in several countries, including Japan and the USA. Recent studies
demonstrated that somatic mutations within the ATP-binding
pocket of the tyrosine kinase domain of the EGFR, including small
in-frame deletions and missense substitutions, are present in a
subset of lung adenocarcinomas and confer susceptibility to the
gefitinib in lung cancer patients (Lynch et al, 2004; Paez et al,
2004). However, EGFR mutation was found to be generally rare
in most malignancies except lung cancers, and gefitinib-sensitive
cancers without EGFR mutations have been reported in HER2-
overexpressing breast cancer cell lines as representative examples
(Moasser et al, 2001; Moulder et al, 2001). To date, however, the
sensitivity of HER2-overexpressing gastric cancers to gefitinib
remains essentially unknown.
Recently, we found that the HER2 positivity rate was
significantly higher in gastric cancer liver metastasis than in
primary tumours. Based on this clinical observation and the
experimental evidences that some HER2-overexpressing breast
cancer cell lines are sensitive to gefitinib, we speculated that HER2-
overexpressing gastric cancer liver metastases were susceptible
to gefitinib. To test this possibility, we established three new
HER2-overexpressing gastric cancer cell lines (GLM-1, GLM-2 and
GLM-4) derived from liver metastasis (Nakanishi et al, 2005)
and examined the sensitivity of these cell lines to gefitinib. As
expected, all the HER2-overexpressing gastric cancer cell lines
exhibited high sensitivity to gefitinib both in vitro and in vivo.
Here we report on the mechanism underlying the sensitivity and
acquired resistance of these cell lines to gefitinib, and discuss
possible molecular targeting therapy against patients with HER2-
overexpressing gastric cancer liver metastasis.
MATERIALS AND METHODS
Compounds
Gefitinib (ZD1839; Iressa) was provided by AstraZeneca (Maccles-
field, UK). Trastuzumab (Herceptin, Genentech, CA, USA), a
humanised anti-HER2 monoclonal antibody, was purchased from
Chugai Pharmaceuticals (Tokyo, Japan). Human recombinant EGF
and heregulin were obtained from R&D Systems (Mineapolis, MN,
USA). Phosphatidylinositol-3-kinase (PI3K) inhibitor (LY294002)
and mitogen-activated protein/extracellular signal-regulated kinase
kinase (MEK) 1/2 inhibitor (U0126) were obtained from Cell
Signaling Technology (Beverly, MA, USA). Antibodies used were as
follows: for Western blotting analysis, mouse monoclonal anti-
bodies to total Erk1/2 and phospho-Erk1/2 (Thr202/Tyr204),
rabbit polyclonal antibodies to total Akt, phospho-Akt (Ser473)
and to PTEN (phosphatase and tensin homologue gene) (Cell
Signaling Technology, Beverly, MA, USA); mouse monoclonal
antibody to HER2 (Cell Signaling Technology), HER3 (clone 2F12,
Upstate, Lake Placid, NY, USA), and a-tubulin (clone DM1A,
Sigma-Aldrich); rabbit polyclonal antibody to CXCR4 (Abcam Ltd,
Cambridge, UK). For immunohistochemistry, mouse monoclonal
antibody to EGFR (Novocastra Labs, Newcastle, UK), rabbit
polyclonal antibody to HER2 (DAKO Cytomation, Glostrup,
Denmark) and HER3 (Ab-10, NeoMarkers, Fremont, CA, USA)
and rabbit monoclonal antibody to phospho-Akt (Ser473) (736E11,
Cell Signaling Technology) were used. For flow cytometry, mouse
monoclonal antibody to EGFR (NeoMarkers) was used.
Tissue samples
Sixty-four primary stomach tumours from stage II–III gastric
cancer patients who underwent gastrectomy between 1995 and
1996, and 20 metastatic liver tumours from stage IV gastric cancer
patients who underwent partial hepatectomy (17 patients), biopsy
(two patients) and autopsy (one patient) during 1991 and 2005 in
the Department of Gastroenterological Surgery, Aichi Cancer
Center Hospital were used in this study, which was approved by
the Institutional Ethical Committee of the Aichi Cancer Center.
Cell lines
GLM-1 and GLM-2 cell lines were recently established in our
laboratory from liver metastasis of Japanese gastric cancer patients
who were surgically resected in Aichi Cancer Center Hospital as
reported previously (Nakanishi et al, 2005). GLM-4 is a newly
established cell line in our laboratory from liver metastases
obtained from a 65-year-old Japanese man suffering from stage IV
gastric cancer with multiple liver metastasis at autopsy. These
tumour tissues were obtained from patients or their family with
written informed consent. Establishment of each cell line was
performed according to the method described previously (Naka-
nishi et al, 1995). Other human gastric cancer cell lines derived
from liver metastases from a Caucasian gastric cancer patient
(NCI-N87) were obtained from ATCC (Manassas, VA, USA). The
conventional human gastric cancer cell lines, GCIY, MKN-28,
MKN-45 and MKN-74 were obtained from RIKEN Cell Bank
(Tsukuba, Japan). HSC-43 cell line was kindly provided by Dr
K Yanagihara (National Cancer Center Research Institute, Tokyo,
Japan). These cell lines were maintained in DMEM (Nissui
Pharmaceutical Co., Ltd, Tokyo, Japan) or RPMI1640 (Sigma, St
Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS)
(GIBCO, Grand Island, NY, USA), 100Uml
 1 penicillin and
100mgml
 1 streptomycin in plastic dishes (Falcon, Franklin Lakes,
NJ, USA), and incubated at 371Ci n5 %C O 2. GLM-2 and GLM-4
lines were cultured in type I collagen-coated dishes (IWAKI, Asahi
Techno Glass, Japan). A subclone of GLM-1 cells resistant to
gefitinib (GLM-1R) was isolated after four cycles of a selection
treatment consisting of continuous exposure of parental cells to
1mM gefitinib for 1–2 weeks, followed by permitting regrowth of
surviving cells and subsequent passage in vitro for each.
In vitro cell growth assay
Cells were harvested with trypsin/EDTA, plated at 5 10
4cells per
24-well plastic plate or type I collagen-coated plate (for GLM-2 and
GLM-4 cells) in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% FBS, and then treated with increasing
doses of gefitinib (0.01, 0.1, 1 and 10mM) or trastuzumab (0, 1, 10,
and 100mgml
 1) on days 1 and 3. The number of viable cells was
counted on day 4 with a hemocytometer in triplicate.
Cell cycle analysis by flow cytometry
To determine the percentage of cells at various phases of cell cycle,
exponentially growing cells were treated with gefitinib at a
concentration of 10mM for 24h, untreated control and gefitinib-
treated cells (1 10
6) were analysed for nuclear DNA after
propidium iodide staining using CycleTEST Plus Kit (Becton
Dickinson, San Jose, CA, USA) according to the manufacturer’s
instructions. Flow cytometric analysis was performed in FACSCa-
libur (Becton Dickinson). Data collected from 10000 cells for each
experiment were analysed by ModFit software (Verity Software
House, Topsham, ME, USA).
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sApoptosis assay
Apoptosis induced by gefitinib was quantitated by measuring
caspase-3/7 activity using Apo-onet Homogeneous Caspase-3/7
Assay Kit (Promega Corp., Madison, WI, USA). Cells were
harvested with trypsin/EDTA and were plated at 1 10
4cells per
96-well plastic plate or type I collagen-coated plate (for GLM-2 and
GLM-4 lines) in DMEM and treated with increasing doses of
gefitinib (0, 0.1, 1 and 10mM), LY294002 (0, 1, 10 and 50mM) and
U0126 (0, 1, 10 and 50mM) on day 1 in the presence of 10% FBS.
After 24h, caspase-3/7 activity of the cells was then measured by
adding an aliquot of the Homogeneous Caspase-3/7 reagent to
each well, shaking the plate for 1h at room temperature, and
measuring the fluorescence intensity by a fluorescent plate reader
(Wallac Co., Turku, Finland). Inhibition of gefitinib-induced
apoptosis by Caspase-3 tetrapeptide inhibitor, DMQD-CHO
(Peptide Institute, Osaka, Japan) was examined by the pretreat-
ment of cells plated in 96-well plates with increasing doses of
DMQD-CHO (0, 1, 10mM) for 1h, followed by the treatment with
increasing doses of gefitinib (0, 0.1, 1 and 10mM).
Western blot analysis
The monolayer culture cells were maintained on 60mm dishes in
medium supplemented with 10% FBS. To evaluate the effects of
gefitinib under ligand-mediated stimulation, cells were incubated
in serum-free medium for 24h, and exposed to gefitinib at
increasing concentrations (0, 0.1, 1 and 10mM) for 2h at 371C.
Unless otherwise indicated, cancer cells were incubated for
different time periods with either EGF or heregulin (10 or
50ngml
 1). Cells were then lysed at 41C in lysis buffer (10mM
Tris-HCl, pH 7.5, 150mM NaCl, 1% Triton X-100, 1mM EDTA and
complete Protease Inhibitor Cocktail). Protein concentration was
determined by Lowry assay (DC Protein Assay; Bio-Rad, Hercules,
CA, USA), and 10mg cell aliquots were directly lysed in Laemmli
sample buffer for subsequent immunoblotting with antibodies as
described previously (Ikehara et al, 2004). In brief, whole cell
lysates were separated by SDS–PAGE under reducing conditions,
and transferred to polyvinylidene difluoride membranes (Amersham-
Pharmacia Biotech, Buckinghamshire, UK) and immunoblotted
with antibodies described above. Bound antibodies were visualised
using Western Lightning Chemiluminescence Plus (PerkinElmer
Life Sciences, Boston, MA, USA).
Cell-based detection of phosphorylation of Akt and Erk by
ELISA
Alteration of Akt and Erk1/2 phosphorylation by treatment with
specific inhibitor was directly measured on 96-well cultured cells
using a cell-based ELISA assay as described previously (Versteeg
et al, 2000). Cells were seeded at 1 10
4cells per 96-well plastic
plate on day 0 and allowed to grow in the presence of 10% FBS for
24h. On day 1, the relevant cells were treated with inhibitors such
as PI3K inhibitor (LY294002) and MEK 1/2 inhibitor (U0126) for
2h, and then phospho-protein and total protein were quantitated
by the Cellular Activation of Signaling ELISA (CASE Kit, Super-
Array Bioscience, Frederick, MD, USA) following the manufac-
turer’s instruction. Briefly, the treated cells were fixed in 4%
formaldehyde in phosphate buffered saline (PBS), quenched with
buffer containing H2O2 and NaN3, followed by blocking non-
specific reactions for 1h. Primary antibody specific for both
phospho-Akt (Ser473) and pan-Akt was then added to two
identical sets of each well and incubated for 1h at room
temperature. After washing with PBS, the wells were incubated
with HRP-conjugated secondary antibody for 1h, and the colour
was developed with 10min incubation at room temperature and
measured at 450nm absorbance on a plate reader.
Sequence analysis of EGFR and HER2 gene
Total RNAs from GLM-1 and GLM-2 cells were extracted using the
RNAeasy kit (Qiagen, Valencia, CA, USA). Complementary DNAs
were synthesised with oligo (dT) primers in a 20ml total volume
reaction mixture using a superscript preamplification system
(Invitrogen, Carlsbad, CA, USA). RT–PCR was performed with
high-fidelity KOD polymerase pulse (Toyobo, Osaka, Japan) to
amplify the first four exons (exons 18–21) of the seven exons
(exons 18–24) that code for TK domain of the EGFR and HER2
gene. The PCR products were purified and subjected to the cycle-
sequence with the Big Dye Terminator v3.1 cycle sequence kit
(Applied Biosystems, Foster City, CA, USA).
Immunohistochemical analysis
Subcutaneous tumours formed 1 month after injection of tumour
cells into male nude mice of KSN strain were removed and fixed in
10% buffered formalin for 24h. Formalin-fixed and paraffin-
embedded sections (4mm) were used for immunohistochemistry
and fluorescence in situ hybridisation (FISH). For antigen
retrieval, the sections were treated with microwave at 981C for
10min. After blocking nonspecific reactions, the sections were
incubated at 41C overnight with antibodies to EGFR, HER2 and
HER3 with optimal dilution. After washing with PBS, the sections
were incubated with biotinylated secondary antibodies for 30min.
The sections were washed again with PBS, then incubated with
streptavidin–peroxidase complex (Vectastain ABC kit, Vector
Laboratories, Burlingame, CA, USA) for 60min. The chromogen
was developed with 0.01% diaminobenzidine (DAB), and the
sections were counterstained with Meyer’s hematoxylin. Immuno-
histochemistry for HER2 as described above is a conventional
method with a three-step visualisation system which is similar to
HercepTest (Dako Cytomation, Carpinteria, CA, USA) in terms of
the use of the same polyclonal antibody and estimation system, but
is different from HercepTest in the antigen retrieval method and
visualisation method. EGFR and HER2 protein expression was
scored for each of the 3þ,2þ,1þ and 0 categories based on the
membrane staining according to the criteria of HercepTest.
Tumours with staining scores of 2þ and 3þ were evaluated as
positive. Histology was simply subdivided into the intestinal type
and diffuse type according to Lauren’s classification.
FISH analysis
Amplification of the c-erbB-2 gene was determined by dual-colour
FISH method using the Passvision HER-2 DNA probe Kit (Vysis
Inc. Downers Grove, IL, USA) according to the manufacturer’s
protocol. The HER-2/neu-Spectrum Orange probe contains a DNA
sequence specific for the c-erbB-2 human gene locus and
hybridises to region 17q11.2–q12 of human chromosome. The
CEP 17 (chromosome enumeration probe 17)/Spectrum Green
probe used as a control contains alpha-satellite DNA that
hybridises to the D17Z1 locus (centromere region of chromosome
17). The nucleus was counterstained with 40,6-diamidino-2-
phenylindole (DAPI). The slides were observed under BX60
fluorescence microscope equipped with digital camera (DP50)
(Olympus, Tokyo, Japan), and the images were captured on a
Windows PC with Viewfinder Lite software. A cell was considered
to show amplification when a definite cluster or more than 10
signals for c-erbB-2 was found.
Tumour xenograft studies
To examine antitumour activity of gefitinib in vivo, growing cells
were harvested with trypsin–EDTA, washed with PBS, and 5 10
6
cells in 0.2ml PBS were injected subcutaneously into the left
abdominal flanks of 8-week-old male nude mice of KSN strain
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tained under specific-pathogen-free (SPF) conditions. Mice (n¼5)
were orally administered gefitinib with a gastric tube at a dose of 0,
100 or 150mg per kg per day from day 10 after injection, five times
per week for 3–6 weeks. In the control groups, mice were orally
administered vehicle (0.5% Polysorbate, Merck, Damstadt,
Germany) in the same manner. In the treatment with trastuzumab,
mice were given intraperitoneal injection at a dose of 20mg per kg
per day, twice a week for 6 weeks. Tumour maximum diameter (L)
and the right angle diameter to that axis (W) were measured every
week. Tumour volume was estimated by the following formula,
L W W 1/2. All experiments were carried out with the
approval of the Institutional Ethical Committee for Animal
Experiment of Aichi Cancer Center Research Institute and met
the standard as defined by the UKCCR guidelines (Workman et al,
1998).
Statistical analysis
The statistical significance of the differences in data between each
treatment groups was determined by applying Student’s t test.
Differences in the incidence between the groups were analysed
with w
2 test or Fisher’s exact test. A P-value o0.05 was considered
significant.
RESULTS
Incidence of HER2 overexpression in primary and
metastatic liver tumours
HER2 positivity rate (65%), as determined by immunohisto-
chemistry, was significantly higher in the metastatic liver tumours
than in the primary tumours of the stomach (38%) (Po0.05).
Histologically, HER2 positivity rate was higher in intestinal type
than diffuse type, particularly in intestinal-type liver metastatic
lesions (90%). In contrast, EGFR and HER3 positivity rate did not
differ between primary tumours and liver metastasis ranging from
25 to 30% in gastric cancer patients, indicating selective over-
expression of HER2 in metastatic liver tumours.
HER2 overexpression in human gastric cancer cell lines
derived from liver metastasis
Immunohistochemistry of nude mouse xenografts showed that all
the liver metastasis-derived intestinal-type gastric cancer cell lines
(GLM-1, GLM-2, GLM-4 and NCI-N87) overexpressed HER2 on
their cell surface, and were judged as positive (2þ or 3þ) based
on the criteria of HercepTest (Figure 1A). In contrast, HER2
expression of other gastric cancer cell lines including the diffuse-
type (MKN-45 and HSC-43) and intestinal-type cell lines (MKN-28
and MKN-74) was low and judged as negative (0 or 1þ). Moderate
HER3 expression in the cytoplasm together with cell surface was
also observed in GLM-1, GLM-4 and NCI-N87 cells. In contrast,
EGFR overexpression was observed only in NCI-N87 cells (data not
shown). Western blot analysis confirmed apparent overexpression
of HER2 in GLM-1, GLM-2, GLM-4 and NCI-N87 cells along with
EGFR expression in NCI-N87 cells, and HER3 expression in
GLM-1, GLM-2 and NCI-N87 cells (Figure 1B). FISH analysis
clearly demonstrated HER2 gene amplification in a cluster pattern
in GLM-1, GLM-4 and NCI-N87 cells, but not GLM-2 cells
(Figure 1C). Furthermore, expression of CXCR4, which is known
to be upregulated by HER2 overexpression, was found to be
slightly increased in HER2-overexpressing cancer cell lines
(Figure 1B).
Growth inhibition and apoptosis induction by gefitinib in
HER2- overexpressing cells
The growth of HER2-overexpressing cell lines (GLM-1, GLM-2,
GLM-4 and NCI-N87) in vitro was markedly inhibited by gefitinib
with IC50 of 0.028, 0.32, 0.078 and 0.091mM, whereas most of
the HER2 low-expressing gastric cancer cell lines (GCIY, MKN-28,
MKN-45, MKN-74) were resistant to gefitinib with IC50 more than
10mM (Figure 2A), indicating a correlation between degree of
HER2 expression and gefitinib sensitivity in gastric cancer cell
A B
GLM-2 GLM-1
GLM-1
MKN-74
MKN-45
MKN-28
HSC-43
GLM-2
GLM-4
NCI-N87
EGFR
HER2
GLM-4 NCI-N87 HER3
C CXCR4
GLM-1
PTEN
GLM-2
GLM-4 NCI-N87
-Tubulin
Figure 1 HER2 overexpression in human gastric cancer cell lines derived from liver metastasis. (A) HER2 expression determined by
immunohistochemistry of xenografts in nude mice formed after subcutaneous injection of GLM-1, GLM-2, GLM-4 and NCI-N87 cells. Note the strong
membranous staining in these cells. (B) Expression of EGFR, HER2, HER3, CXCR4 and PTEN as determined by Western blotting of cultured cell lysates. (C)
Amplification of HER2 gene determined by dual-colour FISH of xenografts in nude mice. HER2 gene amplification in a cluster pattern (red) was observed in
GLM-1, GLM-4 and NCI-N87 cells.
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slines. Cell cycle analysis by a flow cytometer showed that gefitinib
treatment (10mM) resulted in the depletion of S phase cells from
16.5 to 3.2%, accumulation of G0–G1 phase cells (83.4–96.8%) and
virtually no change in G2–M phase cells. This indicated the weak
induction of G1 arrest of cell cycle in HER2-overexpressing GLM-1
cells by gefitinib. On the other hand, the proportion of each stage
of the cell cycle in HER2 low-expressing MKN-28 cells changed
from 18.9 to 23.4% in S phase cells, from 75.5 to 71.7% in G0-G1
phase cells, and from 5.6 to 4.9% in G2-M phase cells after gefitinib
treatment. Thus, there was no indication of G1 arrest by gefitinib in
HER2 low-expressing MKN-28 cells (Figure 2B). Furthermore,
caspase-3/7 assay revealed that gefitinib induced apoptosis in
HER2-overexpressing cancer cell lines in a dose- and time-
dependent manner (Figure 2C). Caspase 3-dependent apoptosis
induction by gefitinib was confirmed by the suppression of
gefitinib-induced apoptosis with a caspase-3 inhibitor (DMQD-
CHO) (data not shown).
The effect of gefitinib on the growth of tumour xenograft in
nude mice was also examined. Daily oral administration of
gefitinib (150mgkg
 1, five times a week) significantly suppressed
tumour growth of HER2-overexpressing cells (GLM-1, GLM-4 and
NCI-N87) in a dose-dependent manner, whereas no significant
inhibition of tumour growth was observed with HER2 low-
expressing cell lines (MKN-28) (Figure 2D). HER2-overexpressing
GLM-2 cells, without gene amplification, have no tumorigenicity in
nude mice.
Effects of PI3K inhibitor and MEK inhibitor on the
apoptosis induction
The basal apoptotic rate was significantly higher in HER2-
overexpressing cell lines (GLM-1, GLM-2, GLM-4 and NCI-N87)
than HER2 low-expressing cell line (MKN-28) in the absence of
apoptosis-inducing stimuli (Po0.001) (Figure 3). Marked en-
hancement of apoptosis by a specific inhibitor for PI3K
(LY294002) was observed in HER2-overexpressing cell lines
(Po0.001), but not MKN-28 cell line (Figure 3A). MEK1/2
inhibitor (U0126) only partially enhanced apoptosis in GLM-2,
GLM-4 and MKN-28 cells (Figure 3B). However, ELISA assay for
protein-phosphorylation revealed that LY294002 significantly
reduced phospho Akt, but not total Akt, in a dose-dependent
manner in both HER2-overexpressing and HER2 low-expressing
cells (Figure 3C), indicating that HER2-overexpressing cells
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Figure 2 Growth inhibition and apoptosis induction by gefitinib in HER2-overexpressing cancer cell lines both in vitro and in vivo.( A) Growth inhibition by
gefitinib in vitro in various human gastric cancer cell lines. Cells were plated in 24-well dish and treated twice with increasing doses of gefitinib, followed by cell
counting after a 4-day culture. (B) Flow cytometric analysis of cell cycle of HER2-overexpressing and low-expressing cells with or without gefitinib treatment.
DNA histogram and % of each cell cycle phase are shown. (C) Apoptosis induction by gefitinib in HER2-overexpressing and low-expressing cells at the
increasing drug concentrations of 0mM (’), 1.0mM ( ) and 10mM (&), as evaluated by measuring caspase 3/7 activity. (D) Inhibitory effects of gefitinib on
the growth of HER2-overexpressing and low-expressing tumour xenografts in nude mice. Tumour cells were injected subcutaneously into nude mice, and
gefitinib was orally administered at a dose of 0 (&), 150mg per kg per day (’), five times per week for 3 weeks. Ns, not significant; *Po0.01; **Po0.001
(vs control). Bars¼s.e.
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sdepend for their survival on the PI3K/Akt pathway rather than the
MAPK pathway as major downstream signalling pathways.
Effects of gefitinib on EGFR downstream signalling
pathways
HER2-overexpressing cell lines were supposed to upregulate the
antiapoptotic PI3K/Akt pathway to achieve their growth and
survival. To further clarify this point, we next examined the
phosphorylation of Akt and Erk1/2 in HER2-overexpressing cells
by Western blotting. EGF induced phosphorylation of Akt slightly,
and Erk1/2 significantly, in GLM-1 cells, whereas heregulin
induced significant phosphorylation only in Erk1/2. Such a
ligand-induced phosphorylation was effectively inhibited by
gefitinib at a concentration of 1.0mM (Figure 4A). Similar results
were obtained from other HER2-overexpressing cell lines (GLM-2
and GLM-4). Furthermore, Akt, not Erk1/2, was constitutively
phosphorylated in the absence of ligand stimulation. This
constitutive phosphorylation of Akt was observed in both HER2-
overexpressing and low-expressing cancer cell lines, but significant
inhibition of the phosphorylation by gefitinib was observed only in
HER2-overexpressing cell lines (Figure 4B). Expression of total
PTEN, as well as phosphorylated PTEN, an antagonist of PI3K
function and negatively regulates Akt activities, was not different
between HER2-overexpressing and low-expressing cell lines
(Figure 1B), indicating that PTEN is not involved in the
constitutive activation of PI3K/Akt pathway in HER2-overexpres-
sing cells.
Effects of trastuzumab on the growth of HER2-
overexpressing cells both in vitro and in vivo
Although growth inhibition of HER2-overexpressing cancer cell
lines by trastuzumab (1–100mgml
 1) with maximally 50% of
control was observed in vitro, it was less extensive than that by
gefitinib (Figure 5A vs Figure 2A). Anti-tumour effect on the
subcutaneously transplanted tumour (GLM-1) in nude mice was
also observed by trastuzumab treatment, but was less extensive
than by gefitinib. Furthermore, trastuzumab treatment in combi-
nation with gefitinib enhanced the antitumour effect of gefitinib
additively. In contrast, such inhibitory effect of trastuzumab was
not observed in the xenograft of the HER2 low-expressing cancer
cell line (MKN-45) (Figure 5B).
Isolation of gefitinib-resistant cell line, GLM-1R, from
GLM-1
GLM-1 tumour xenograft in nude mice was not completely
abolished by prolonged gefitinib treatment. To investigate such a
acquired resistance of a gastric cancer cell line to gefitinib, we
isolated the gefitinib-resistant cell line, GLM-1R, from parental
GLM-1 cells by four cycles of selection of GLM-1 cell under
exposure to gefitinib (1.0mM) for 2 weeks in vitro. GLM-1R cells
were found to have a 65-fold higher IC50 for gefitinib (IC50¼1.82
vs 0.028mM) (Figure 6A) and showed a significantly lower
apoptosis induction by gefitinib than the parental cell line (data
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Figure 3 Effects of PI3K inhibitor (LY294002) and MEK inhibitor
(U0126) on apoptosis induction and Akt phosphorylation of HER2-
overexpressing and low-expressing cancer cell lines. (A) Apoptosis
induction by LY294002. Cells were plated at 1 10
4cells per 96-well
dish and LY294002 concentrations of 0mM (&), 10mM () , 5 0 mM (’)
were added 1 day after seeding and cultured for 24h. Apoptosis was
measured with caspase 3/7 assay. (B) Apoptosis induction by U0126 at
concentrations of 0mM (&), 10mM () , 5 0 mM (’). (C) Inhibition of Akt
phosphorylation by LY294002. Cells were plated at 1 10
4cells per 96-
well dish in the presence of 10% FBS and 1 day after seeding, LY294002 at
respective concentrations of 0mM (&), 10mM () , 5 0 mM (’) were added
and cultured for 2h. Phosphorylated Akt (pAkt) and total Akt (T Akt) were
measured with AKT 473 ELISA Kit. NS, not significant; *Po0.01;
**Po0.001 (vs control). Bars¼s.e.
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Figure 4 Effects of gefitinib on MAPK and PI3K/Akt signalling pathways in
HER2-overexpressing cancer cell lines. (A) GLM-1 cells were cultured in
serum-free medium for 24h and exposed to gefitinib at increasing
concentrations for 2h at 371C. Cells were then incubated with either EGF
or heregulin (10 or 50ngml
 1) for 10min, lysed at 41C in lysis buffer and
subjected to SDS–PAGE, transferred to membrane. Immunoblot analyses
were performed with specific antibodies against the phosphorylated Akt
and Erk1/2. (B) Gastric cancer cell lines with HER2 overexpression (left)
and low expression (right) were cultured in serum-free medium for 24h
and then treated with either gefitinib (1mM) or vehicle for 2h.
Phosphorylation of Akt was analysed by Western blot. Immunoblot with
a-tubulin antibody was performed to evaluate protein loading.
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snot shown). In addition, the growth inhibition of GLM-1R tumour
xenograft in nude mice by gefitinib was no longer significant
(Figure 6B).
EGFR expression and downstream signalling in GLM-1R
cells
GLM-1R tumour xenografts in nude mice exhibited more
differentiated histology with well-defined tubular structures and
stronger membranous staining of EGFR than parental GLM-1
tumour (Figure 6C), whereas HER2 expression remained un-
changed between the two. Flow cytometric analysis confirmed that
EGFR expression was significantly increased in GLM-1R cells as
compared with parental GLM-1 cells (data not shown). Western
blot analysis revealed that phosphorylation of Shc and Erk1/2,
but not Akt, increased in GLM-1R cells in the absence of ligand
stimulation as compared with parental GLM-1 cells (Figure 6D),
indicating moderate, but constitutive activation of EGFR-MAPK
signalling pathway in GLM-1R cells. Furthermore, a 10-fold higher
concentration of gefitinib was needed for effective inhibition of
phosphorylation of Akt in GLM-1 cells when EGF ligand
stimulation increased from 10 to 50ngml
 1 (data not shown),
suggesting that the acquired resistance of GLM-1R cells to gefitinib
may be due to the autocrine activation of the EGFR-MAPK
pathway in compensation for PI3K/Akt pathway.
Expression of EGFR, HER2 and pAKT in liver metastases
from gastric cancer patients
To strengthen the HER2-driven constitutive activation of PI3K/Akt
pathway in HER2-overexpressing cells in vitro, we examined
the expression of phosphorylated Akt in the archived clinical
specimens of liver metastasis from 20 gastric cancer patients,
immunohistochemically. As shown in Table 1, HER2
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C
e
l
l
 
n
u
m
b
e
r
 
 
(
%
 
o
f
 
c
o
n
t
r
o
l
)
Trastuzumab  (g ml–1)
(%)
GLM-1
GLM-2
GLM-4
NCI-N87
MKN-28
MKN-45
HSC-43
0
20
40
60
80
100
0 1 10 100
A
0
500
1000
1500
2500
1W 2W 3W 4W 5W 6W
MKN-45
0
1000
2000
3000
4000
5000
Gefitinib
Trastuzumab
Combination
Control
Gefitinib
Trastuzumab
Combination
Control
1W 2W 3W 4W 5W 6W
*
**
*
*
** ** *
2000
T
u
m
o
u
r
 
v
o
l
u
m
e
 
(
m
m
3
)
T
u
m
o
u
r
 
v
o
l
u
m
e
 
(
m
m
3
)
Weeks Weeks
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soverexpression was correlated with expression of phosphorylated
Akt with marginal significance whereas EGFR overexpression was
not correlated.
DISCUSSION
In the present study, we found overexpression of HER2 in gastric
cancer liver metastasis at a significantly higher incidence than
primary tumour in the stomach. We newly established three
HER2-overexpressing gastric cancer cell lines (GLM-1, GLM-2 and
GLM-4) from such liver metastasis of Japanese patients (Nakanishi
et al, 2005), and demonstrated for the first time that they were
highly sensitive to gefitinib rather than trastuzumab. In fact,
gefitinib induced remarkable apoptosis in these HER2-overexpres-
sing cells, that has never been observed in conventional gastric
cancer cell lines without HER2 overexpression. We then examined
another HER2-overexpressing intestinal-type gastric cancer cell
line, NCI-N87, derived from liver metastasis of a Caucasian patient
(Park et al, 1990), and confirmed the high gefitinib sensitivity
such as that found in the GLM series. Interestingly, most of these
HER2-overexpressing cell lines express CXCR4, which is report-
edly associated with haematogenous metastasis in breast, colon
and prostate cancer patients (Muller et al, 2001; Brand et al, 2005),
and is known to be regulated by HER2 through the PI3K/Akt
pathway (Li et al, 2004). These clinicopathological findings
strongly suggest that HER2-overexpressing gastric cancer liver
metastases are a unique clinical entity sharing the same
characteristics, for example, morphology (intestinal type), meta-
static potential (CXCR4 expression) and gefitinib sensitivity, and
therefore, may be a good therapeutic target for gefitinib. According
to the past international Phase II randomised clinical trial
consisting of 75 stage IV gastric cancer patients (32 Japanese and
43 non-Japanese from Europe, Australia and Singapore), the result
was quite pessimistic, showing the absence of a complete response
(0%), a very low partial response rate (1.4%), and a low rate of
stable disease (17%); the overall therapeutic efficacy of gefitinib was
quite low (18.3%) (Doi et al, 2003; Rojo et al, 2003). In this trial,
however, no patient selection based on the prediction of gefitinib
sensitivity was performed. Therefore, it is reasonable to assume
that, if HER2-overexpressing gastric cancer patients with liver
metastasis are prospectively selected, the response rate of gastric
cancer patients owing to gefitinib may be significantly increased.
The important issue in this study is the demonstration of the
possible mechanism and biological significance of constitutive
activation of PI3K/Akt pathway in the HER2-overexpressing
gastric cancer cell lines. Several things might explain the
mechanism of constitutive activation of PI3K/Akt pathway. PTEN,
a phosphatase converting PIP3 to inactive PIP2 antagonises PI3K
function and negatively regulates Akt activities. Thus, loss of PTEN
function owing to mutations, haploinsufficiency from LOH and
hypermethylation, which are known to be present in 30–40% of
gastric cancers (Kang et al, 2002; Oki et al, 2005), can lead to the
constitutive activation of PI3K/Akt pathway. In this study,
however, PTEN protein expression in both total and phosphory-
lated form was not downregulated as compared with HER2 low
expressing gastric cancer cell lines, suggesting that PTEN is not
involved in the constitutive activation of PI3K/Akt pathway in
HER2-overexpressing cells. On the other hand, a recent study on
the crystal structure of HER2 protein demonstrated that HER2 has
a fixed conformation that resembles a ligand-activated state and
can interact with other HER receptors such as EGFR and HER3 in
the absence of direct ligand binding (Cho et al, 2003). Alimandi
et al (1995)Previously reported the increased recruitment of PI3K
by the formation of HER2/HER3 heterodimer in a co-transfection
experiment with HER2 and HER3. Furthermore, Arteaga et al
demonstrated HER2/HER3 heterodimer formation, the association
of p85 subunit of PI3K with HER3 and subsequent PI3K/Akt
activation in HER2-overexpressing breast cancer cell lines
(Moulder et al, 2001; Anido et al, 2003). Based on these findings,
it is reasonable to speculate that overexpression of HER2, together
with relatively high expression of HER3 in GLM-1, GLM-2 and
NCI-N87 cells, can promote HER2/HER3 heterodimer formation,
followed by association of HER3 with PI3K, which in turn induce
the constitutive activation of the downstream PI3K/Akt pathway.
As for biological significance of this activation, we found that PI3K
inhibitor (LY294002), not MEK1/2 inhibitor (U0126), abolished
phosphorylation of Akt and induced strong apoptosis in HER2-
overexpressing cells, whereas PI3K inhibitor reduced phosphor-
ylation of Akt without inducing apoptosis in HER2 low-expressing
cells. This suggests that HER2-overexpressing cell lines strongly
depend for their survival on the constitutively activated PI3K/Akt
pathway as a predominant downstream signalling pathway,
whereas HER2 low-expressing cells use multiple signalling path-
ways other than the PI3K/Akt pathway for their survival.
Although HER2-overexpressing gastric cancer cell lines thus
far proved to addict to the self-activated PI3K/Akt pathway, it is
still somewhat puzzling that gefitinib is a tyrosine kinase inhibitor
specific for EGFR, yet exhibits a marked antitumour effect against
HER2-, but not EGFR- overexpressing gastric cancer cells. Anido
et al (2003) reported the gefitinib-sensitive HER2- overexpressing
breast cancer cell lines and proposed the hypothesis that gefitinib
abolishes the formation of HER2/HER3 heterodimers by promot-
ing sequestration of HER2 and HER3 into inactive (unphos-
phorylated) EGFR/HER2 and EGFR/HER3 heterodimer. In the
present study, we found that gefitinib can selectively abolish
constitutive phosphorylation of Akt only in HER2-overexpressing
cells, although HER2 low-expressing cells also show constitutive
activation of the PI3K/Akt pathway, suggesting that gefitinib can
selectively block constitutively activated PI3K/Akt pathway only in
the case simply driven by HER2 overexpression along with
relatively high expression of HER3, which permit to form HER2/
HER3 heterodimer. This finding is consistent with the reports by
Anido et al, but further study is warranted to prove this point. On
the other hand, we found that three of four HER2-overexpressing,
gefitinib-sensitive gastric cancer cell lines have HER2 gene
amplification. Therefore, an alternative explanation for the high
gefitinib sensitivity, specific for HER2-overexpressing gastric
cancer cell lines, is that these lines have other concomitant genetic
changes such as somatic mutations within the ATP-binding pocket
of the tyrosine kinase domain of EGFR (or HER2), which is known
to confer susceptibility to gefitinib in lung adenocarcinoma
patients as reported previously (Sordella et al, 2004; Stephens
et al, 2004; Mitsudomi et al, 2005). In the present study, however,
we could not detect any mutations in EGFR and HER2 tyrosine
kinase domain of GLM-1 and GLM-2 cells, such as small in-frame
deletions and missense substitutions, which might rule out the
possibility of mutations as the cause of gefitinib sensitivity.
Table 1 Immunohistochemical analysis of EGFR, HER2 and phosphory-
lated Akt (pAkt) expression in metastatic liver tumours from 20 gastric
cancer patients
pAkt
Staining No. of patients examined ( ) (+) P-value
HER2
( ) 7 6 1 0.057
a
(+) 13 4 9
EGFR
( )1 6 8 8 40.999
(+) 4 2 2
aw
2 test, P-value¼0.0191, Fisher’s exact test, P-value¼0.0573.
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sAnother interesting finding in this study is the acquired
resistance of HER2-overexpressing gastric cancer cell lines to
gefitinib. Gefitinib-resistant GLM-1R cells exhibited increased
EGFR expression and more differentiated morphology as com-
pared with parental GLM-1 cells. Shc and Erk1/2, respective
upstream and downstream signalling molecules of the MAPK
pathway, were also upregulated in GLM-1R cells. Furthermore,
inhibition of Akt phosphorylation in parental GLM-1 cells in
response to gefitinib treatment attenuated when Ras/MAPK
pathway was strongly stimulatied by a higher EGF concentration
(50 vs 10ngml
 1). These findings suggest that the EGFR-Ras-
MAPK pathway is constitutively (but moderately) activated in
compensation for the blockade of the HER2-PI3K-Akt pathway in
GLM-1R cells, resulting in persistent growth in the presence of
gefitinib and therefore acquired resistance. Consistent with our
finding, Jones et al reported that IGF-1R signalling pathway serves
as a bypass for the EGFR-MAPK pathway, and is involved in the
acquired resistance to gefitinib in a human breast cancer cell
model (Jones et al, 2004). Second mutations of the tyrosine kinase
domain in EGFR, and gain-of-function mutations in downstream
signalling molecules of Ras/MAPK and PI3K/Akt pathways,
including PTEN, are other potential mechanisms of aquired
resistance to gefitinib (Kobayashi et al, 2005; Koizumi et al,
2005; Shih et al, 2005). In the present study, at least mutations in
EGFR and HER2, and loss of PTEN function were not observed in
GLM-1R cells, suggesting that the compensation for PI3K/Akt
pathway by upregulation of Ras/MAPK pathway is the major cause
of gefitinib resistance in GLM-1R cells. We found that the residual
tumour xenograft in nude mice 1–2 month after gefitinib
treatment also showed upregulation of EGFR. Therefore, GLM-1
cells can acquire resistance to gefitinib after prolonged treatment
in vivo. These findings suggest the potential importance of bi- or
multi-directional inhibition of the PI3K/Akt, Ras/MAPK and other
pathways for more effective treatment of HER2-overexpressing
gastric cancer cell lines. Now, we are also investigating the
antitumour activity of a combination of both inhibitors for PI3K
and MAPK pathway against GLM-1R cells.
In conclusion, we identified for the first time a new clinical
entity – a subset of gastric cancers showing high susceptibility to
gefitinib and liver metastasis. Our immunohistochemical finding
obtained from archived clinical specimens, that Akt pathway
tended to be activated (phosphorylated) in the liver metastasis in
HER2-overexpressing gastric cancer patients, while still prelimin-
ary, suggests that HER2 overexpression, together with constitutive
activation of the PI3K/Akt pathway, may be useful predictive
markers for gefitinib sensitivity in gastric cancers. Therefore,
HER2-overexpressing gastric cancer with liver metastasis would be
a potential target for molecular therapy with gefitinib and related
compounds.
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